Structure-activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity

European Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2011, Pages 3258-3264

  Subramanian, Santhosh ^a   Kim, Nam Soo ^a   Thanigaimalai, Pillaiyar ^a   Sharma, Vinay K ^a   Lee, Ki Cheul ^a   Kang, Jong Seong ^a   Kim, Hwan Mook ^b   Jung, Sang Hun ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Anticancer activity; Antimitotic agent; Arylsulfonylimidazolidinone

Indexed keywords

1 (1 BENZOYL 1,2,3,4 TETRAHYDROQUINOLIN 6 YLSULFONYL) 4 PHENYLIMIDAZOLIDIN 2 ONE; 1 [1 (2 CHLOROACETYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YLSULFONYL] 4 PHENYLIMIDAZOLIDIN 2 ONE; 2 CHLOROETHYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; 4 METHYL 4 PHENYL 1 [1 (2,2,2 TRIFLUOROACETYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YLSULFONYL] 4 PHENYLIMIDAZOLIDIN 2 ONE; 4 PHENYL 1 (1,2,3,4 TETRAHYDROQUINOLIN 6 YLSULFONYL)IMIDAZOLIDIN 2 ONE; 4 PHENYL 1 [1 (2,2,2 TRIFLUOROACETYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YLSULFONYL] 4 PHENYLIMIDAZOLIDIN 2 ONE; 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXAMIDE; 6 (4 METHYL 2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) N [4 (METHYLTHIO)PHENYL] 3,4 DIHYDROQUINOLINE 1(2H) CARBOXAMIDE; ALLYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; ANTINEOPLASTIC AGENT; BUTYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; DOXORUBICIN; ETHYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; IMIDAZOLIDINE DERIVATIVE; ISOBUTYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; METHYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; N (2 CHLOROACETYL) 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXAMIDE; N (4 METHOXYPHENYL) 6 (4 METHYL 2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXAMIDE; N ARYLSULFONYLIMIDAZOLIDINONE DERIVATIVE; N CYCLOHEXYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXAMIDE; PROPYL 6 (2 OXO 4 PHENYLIMIDAZOLIDIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLINE 1(2H) CARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; MOUSE; NONHUMAN; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARYLSULFONATES; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMIDAZOLIDINES; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958255363     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.04.042     Document Type: Article

References (23)

1. S. Honore, E. Pasquier, and D. Braguer Cell. Mol. Life Sci. 62 2005 3039 3056
2. F. Pellegrini, and D.R. Budman Cancer Invest. 23 2005 264 273
3. J. Avila Life Sci. 50 1992 327 334
4. P.K. Sorger, M. Dobles, R. Tournebize, and A.A. Hyman Curr. Opin. Cell Biol. 9 1997 807 814
5. K.H. Downing, and E. Nogales Curr. Opin. Struct. Biol. 8 1998 785 791
6. M. Lehnert Eur. J. Cancer 32A 1996 912 920
7. U.A. Germann Eur. J. Cancer 32A 1996 927 944
8. H.-S. Lee, K.-L. Park, S.-U. Choi, C.-O. Lee, and S.-H. Jung Arch. Pharm. Res. 23 2000 579 584
9. S.-H. Jung, J.-S. Song, H.-S. Lee, S.-U. Choi, and C.-O. Lee Arch. Pharm. Res. 19 1996 570 580
10. S.-H. Jung, J.-S. Song, H.-S. Lee, S.-U. Choi, and C.-O. Lee Bioorg. Med. Chem. Lett. 6 1996 2553 2558
11. S.-H. Jung, and S.-J. Kwak Arch. Pharm. Res. 20 1997 283 287
12. S.-H. Jung, S. H-Lee, J.-S. Song, H.-M. Kim, S.-B. Han, C.-W. Lee, M. Lee, D.-R. Choi, J.-A. Lee, Y.-H. Chung, S.-J. Yoon, E.-Y. Moon, H.-S. Hwang, S.-K. Seong, and D.-K. Lee Bioorg. Med. Chem. Lett. 8 1998 1547 1550
13. S.-H. Jung, K.-L. Park, H.-S. Lee, and J.-S. Whang Arch. Pharm. Res. 24 2001 499 502
14. I.-W. Kim, and S.-H. Jung Arch. Pharm. Res. 25 2002 421 427
15. H.-Y. Park Choo, S. Choi, S.-H. Jung, H.-Y. Koh, and A.-N. Pae Bioorg. Med. Chem. 11 2003 4585 4589
16. I.-W. Kim, C.-K. Lee, H.-S. Kim, and S.-H. Jung Arch. Pharm. Res. 26 2003 9 14
17. S.-H. Jung, H.-S. Lee, N.-S. Kim, H.-M. Kim, M. Lee, D.-R. Choi, J.-A. Lee, Y.-H. Chung, E.-Y. Moon, H.-S. Hwang, S.-K. Seong, and D.-K. Lee Arch. Pharm. Res. 27 2004 478 484
18. S. Kim, J.-H. Park, S.-Y. Koo, J.-I. Kim, M.-H. Kim, E.-J. Kim, K. Jo, H.-G. Choi, S.-B. Lee, and S.-H. Jung Bioorg. Med. Chem. Lett. 14 2004 6075 6078
19. L.V. Rubinstein, R.,H. Shoemaker, K.D. Paull, R.M. Simon, S. Toshini, P. Skehan, D.A. Scudiero, A. Monks, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1113 1118
20. P. Skehan, R. Storeng, D.A. Scudiero, A. Monks, J. McMahon, D.T. Vistica, J.T. Warren, H. Bokesch, F. Kenny, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107 1112
21. C.W. Lee, D.H. Hong, S.B. Han, S.-H. Jung, H.C. Kim, R.L. Fine, S.-H. Lee, and H.M. Kim Biochem. Pharmacol. 64 2002 473 480
22. A. Kamthan, J.H. Scarffe, J. Walling, S. Hatty, B. Peters, R. Coleman, and J.F. Smyth Anticancer Drugs 3 1992 331 335
23. D.D. Perrin, W.L.F. Armarego, and D.R. Perrin Purification of Laboratory Chemicals second ed. 1982 Pergamon Press Oxford, England